The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - AstraZeneca; Daiichi Sankyo; Eisai; Exact Sciences; Gilead Sciences; Lilly; Menarini; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Eisai; Exact Sciences; Gilead Sciences; Lilly; Menarini; MSD; Novartis; Pfizer; Pierre Fabre
Research Funding - AstraZeneca; Roche
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Lilly; MSD; Novartis; Pfizer; Roche; Seagen
Impact of young age at diagnosis on survival outcomes in patients with early breast cancer according to tumor subtype: Pooled analysis of 5 randomized clinical trials from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM).
 
Marta Perachino
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca
Travel, Accommodations, Expenses - Daiichi Sankyo/Astra Zeneca; Lilly; Novartis
 
Eva Blondeaux
Research Funding - Gilead Sciences
 
Michelino De Laurentiis
No Relationships to Disclose
 
Grazia Arpino
Honoraria - AstraZeneca; Daiichi Sankyo; Eisai; Exact Sciences; Gilead Sciences; Lilly; Menarini; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Eisai; Exact Sciences; Gilead Sciences; Lilly; Menarini; MSD; Novartis; Pfizer; Pierre Fabre
Research Funding - Novartis; Pfizer
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Lilly; MSD; Novartis; Pfizer; Roche; Seagen
 
Fabio Puglisi
Honoraria - AstraZeneca; Daiichi Sankyo; Eisai; Exact Sciences; Gilead Sciences; Lilly; Menarini; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Eisai; Exact Sciences; Gilead Sciences; Lilly; Menarini; MSD; Novartis; Pfizer; Pierre Fabre
Research Funding - AstraZeneca; Eisai; Roche
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Lilly; MSD; Novartis; Pfizer; Roche; Seagen
 
Alessandra Fabi
No Relationships to Disclose
 
Stefania Gori
No Relationships to Disclose
 
Francesca Poggio
No Relationships to Disclose
 
Luca Arecco
No Relationships to Disclose
 
Diletta Favero
No Relationships to Disclose
 
Matthew R. Sydes
Honoraria - AstraZeneca; Eisai; Janssen
Research Funding - Astellas Pharma (Inst); Janssen-Cilag (Inst)
 
Matteo Lambertini
Consulting or Advisory Role - AstraZeneca; Exact Sciences; Gilead Sciences; Lilly; Menarini; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Speakers' Bureau - AstraZeneca; Daiichi Sankyo; Gilead Sciences; Ipsen; Knight Therapeutics; Libbs; Lilly; Menarini; Novartis; Pfizer; Roche; Sandoz; Takeda
Research Funding - Gilead Sciences (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo Europe GmbH; Gilead Sciences; Roche
 
Lucia Del Mastro
Honoraria - Lilly; MSD Oncology; Novartis; Roche
Consulting or Advisory Role - Agendia; AstraZeneca; Daiichi Sankyo; Eisai; Exact Sciences; Gilead Sciences; GlaxoSmithKline; Ipsen; Lilly; MSD; Novartis; Olema Oncology; Pfizer; Pierre Fabre; Roche; Seagen
Research Funding - AstraZeneca (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Gilead Sciences (Inst); Lilly (Inst); Novartis (Inst); Olema Oncology; Pfizer (Inst); Pierre Fabre (Inst); Roche (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Pfizer; Roche